Appili Therapeutics Inc (APLIF) Stock Price, Chart & News

Up to 60% off Profit Pro - Limited to first 500 users

Black Friday Sale

Up to 60% off Profit Pro - Limited to first 500 users

60% off Profit Pro - Limited to first 500 users

APLIF

0.03

USD00.00%

Overview

Profile

Statistics

Earnings

Financials

Trends

News

Chart

Latest News

SeekingAlpha

Aditxt signs second amendment to arrangement agreement with Appili Therapeutics

SeekingAlpha

Aditxt signs agreement to acquire Appili Therapeutics

Analysts Recommendations

Bearish

Sell

Strong Buy

Buy

Hold

Sell

Strong Sell

Day Range

0.03USD

52 Week Range

0.01USD

0.05USD

Market Cap

3.15MUSD

About

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

General Information

Type

Common Stock

Exchange

PINK

Currency Code

USD

Currency Name

US Dollar

Country Name

USA

Country ISO

ISIN

CA03783R1073

CUSIP

Sector

Healthcare

Industry

Biotechnology

Fiscal Year End

March

IPO date

Updated At

Highlights

PE Ratio

PEG Ratio

Book Value

-0.09

Dividend Share

Dividend Yield

Earnings Share

-0.02

Wall Street Target Price

0.15

EPS Estimate Current Year

EPS Estimate Next Year

EPS Estimate Current Quarter

EPS Estimate Next Quarter

Most Recent Quarter

Profitability

Revenue TTM

827,407

Gross Profit TTM

1,390,684

EBITDA

-8,590,420

Profit Margin

0.00%

Return On Assets TTM

-244.22%

Return On Equity TTM

-938.72%

Revenue Per Share TTM

0.007

Qtly Revenue Growth YOY

-96.50%

Diluted Eps TTM

-0.02

Qtly Earnings Growth YOY

0.00%

Valuation

Trailing PE

0.00

Forward PE

Price Sales TTM

8.8014

Price Book MRQ

1.4792

Enterprise Value Revenue

Enterprise Value EBITDA

-2

Peers analysis

VRTXVertex Pharmaceuticals Inc
467.80
0.74%
CSLLYCSL Ltd
91.85
0.72%
UCBJYUCB SA ADR
97.79
0.25%
ARGXargenx NV ADR
616.55
0.07%
ARGNFargenx SE
525.60
0.00%

CMXHFCSL Limited
173.75
0.00%
UCBJFUCB SA
174.00
0.00%
BNTXBioNTech SE
118.00
-2.24%
REGNRegeneron Pharmaceuticals Inc
750.00
-0.68%
ALNYAlnylam Pharmaceuticals Inc
253.07
-0.21%

What are you waiting for?Start making profit today

Tools

Plans

Markets

Resources

Compare

Profit mobile app

Discover the world of finance in your pocket

2024